Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D

Go back to Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D

Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025'

March 19, 2025 10:08 AM EDT

Citi analyst Geoff Meacham reiterated a Buy rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD)

The analyst comments "While recent reports (WSJ, Mar 18) suggest the Department of Health and Human Services may cut federal funding for HIV prevention, we believe... More